Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
Nat Rev Cancer
; 3(2): 102-9, 2003 Feb.
Article
em En
| MEDLINE
| ID: mdl-12563309
ABSTRACT
p53 is an attractive therapeutic target in oncology because its tumour-suppressor activity can be stimulated to eradicate tumour cells. Inhibiting the p53-MDM2 interaction is a promising approach for activating p53, because this association is well characterized at the structural and biological levels. MDM2 inhibits p53 transcriptional activity, favours its nuclear export and stimulates its degradation, so inhibiting the p53-MDM2 interaction with synthetic molecules should lead to p53-mediated cell-cycle arrest or apoptosis in p53-positive stressed cells.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Nucleares
/
Genes p53
/
Proteína Supressora de Tumor p53
/
Proteínas Proto-Oncogênicas
/
Neoplasias
Limite:
Humans
Idioma:
En
Revista:
Nat Rev Cancer
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2003
Tipo de documento:
Article
País de afiliação:
Suíça